You will be provided with a research report. The body of the report will contain some citations to references.

Citations in the main text may appear in the following forms:
1. A segment of text + space + number, for example: "Li Qiang constructed a socioeconomic status index (SES) based on income, education, and occupation, dividing society into 7 levels 15"
2. A segment of text + [number], for example: "Li Qiang constructed a socioeconomic status index (SES) based on income, education, and occupation, dividing society into 7 levels[15]"
3. A segment of text + [number†(some line numbers, etc.)], for example: "Li Qiang constructed a socioeconomic status index (SES) based on income, education, and occupation, dividing society into 7 levels[15†L10][5L23][7†summary]"
4. [Citation Source](Citation Link), for example: "According to [ChinaFile: A Guide to Social Class in Modern China](https://www.chinafile.com/reporting-opinion/media/guide-social-class-modern-china)'s classification, Chinese society can be divided into nine strata"

Please identify **all** instances where references are cited in the main text, and extract (fact, ref_idx, url) triplets. When extracting, pay attention to the following:
1. Since these facts will need to be verified later, you may need to look for some context before and after the citation to ensure that the fact is complete and understandable, rather than just a simple phrase or short expression.
2. If a fact cites multiple references, then it should correspond to two triplets: (fact, ref_idx_1, url_1) and (fact, ref_idx_2, url_2).
3. For the third form of citation (i.e., where the citation source and link appear directly in the text), the ref_idx should be uniformly set to 0.
4. If the main text does not specify the exact location of the citation (for example, only the reference list is listed at the end of the article, without specifying the citation point in the text), please return an empty list.

You should return a JSON list format, where each item in the list is a triplet, for example:
[
    {
        "fact": "Text segment from the original document. Note that Chinese quotation marks should use full-width marks. And add a single backslash before the English quotation mark to make it a readable for python json module.",
        "ref_idx": "The index of the cited reference in the reference list for this text segment.",
        "url": "The URL of the cited reference for this text segment (extracted from the reference list at the end of the research report or from the parentheses at the citation point)."
    }
]

Here is the main text of the research report:
## Executive Summary

Therapeutic modulation of plasma metal-ion concentrations is supported in narrow settings: intravenous iron in heart failure with iron deficiency reduced a composite endpoint at 12 months (risk ratio 0.72, 95% CI 0.55–0.89) [1], and sodium–potassium substitution reduced stroke, major cardiovascular events, and death in a high-risk trial (rate ratios 0.86, 0.87, and 0.88) [9].

The same evidence base does not support a broad preventive strategy: EDTA chelation lowered blood lead but did not reduce major adverse cardiovascular events in TACT2 (hazard ratio 0.93, 95% CI 0.76–1.16) [2]; magnesium supplementation lowered blood pressure modestly (systolic −1.25 mmHg; diastolic −1.40 mmHg) without supplied cardiovascular outcome data [3]; selenium effects were surrogate and partly lost significance after multiple-testing correction [5]; and copper and zinc associations were observational rather than proven therapeutic targets [8] [10].

Hepcidin-axis and ferroptosis-directed strategies are described in hematologic disease contexts, but the supplied review provides no cardiovascular outcome evidence and notes infection, anemia, and off-target organ toxicity concerns [7].

## Iron modulation: the clearest cardiovascular signal, but confined to deficiency

Iron deficiency is common in heart failure, affecting up to 50% of patients, and is associated with recurrent hospitalizations and cardiovascular death independently of anemia [4]. A 2025 Bayesian meta-analysis of six randomized trials including 7,175 patients found that intravenous iron versus placebo reduced the composite of recurrent heart-failure hospitalizations and cardiovascular mortality at 12 months (risk ratio 0.72, 95% CI 0.55–0.89) and over the complete follow-up period (risk ratio 0.81, 95% CI 0.63–0.97) [1]. The benefit was driven mainly by fewer recurrent heart-failure hospitalizations (risk ratio 0.69 at 12 months and 0.78 over complete follow-up), whereas cardiovascular mortality was a non-significant trend (hazard ratio 0.80, 95% CI 0.61–1.03 at 12 months; hazard ratio 0.87, 95% CI 0.73–1.04 over complete follow-up) [1]. All-cause mortality did not increase (hazard ratio 0.82, 95% CI 0.65–1.03 at 12 months; hazard ratio 0.92, 95% CI 0.80–1.07 over complete follow-up), and infection and serious adverse-event rates were similar between groups [1].

An earlier meta-analysis pooling AFFIRM-AHF and IRONMAN found a significant reduction in the same composite endpoint (risk ratio 0.81, 95% CI 0.69–0.95; number needed to treat 7) and in recurrent heart-failure hospitalizations (risk ratio 0.77, 95% CI 0.65–0.91; number needed to treat 8) [4]. Cardiovascular death, however, was neutral and statistically fragile in that analysis (odds ratio 0.88, 95% CI 0.71–1.09; power 21%) [4]. The individual trials were also not uniformly positive: AFFIRM-AHF and IRONMAN narrowly missed their primary endpoints in crude analyses, with significance emerging in pre-specified sensitivity analyses, while HEART-FID was significant at a conventional 95% confidence interval but not at a stricter pre-specified 99% interval [1]. This pattern supports a real effect on hospitalization, but it does not establish a definitive mortality benefit.

The clinical role is guideline-supported but condition-limited. The 2025 meta-analysis states that American and European guidelines recommend intravenous iron to improve symptoms and quality of life in heart failure with reduced ejection fraction and iron deficiency [1]. The same analysis notes that treatment effects were greatest in the first year, when average doses were about 2,000 mg, compared with 300–900 mg per year in later years, leaving optimal dosing uncertain [1]. Diagnostic uncertainty also matters: it remains unclear which blood tests best identify iron deficiency, and some trial participants may not have been truly deficient, potentially diluting the observed benefit [1]. Patients with transferrin saturation below 20% had higher event rates and therefore greater absolute benefit, even though relative benefit was similar above and below that threshold [1]. Women showed no statistically significant benefit in a subgroup analysis (risk ratio 0.98, 95% CI 0.75–1.26), which the authors caution may be chance or confounding and requires further study [1].

Safety is reassuring for deficiency correction but not free of formulation-specific concerns. The meta-analysis found no significant increase in infection or serious adverse events [1], and another review reported similar infection, vascular, and injection-site event rates across trials [4]. However, ferric carboxymaltose has been associated with a higher incidence of hypophosphatemia than ferric derisomaltose in iron-deficiency anemia, particularly in women, with effects lasting up to 35 days [4]. The supplied evidence also excluded oral iron substitution from one meta-analysis, so oral iron is not evaluated here as an equivalent cardiovascular intervention [4].

## Toxic-metal chelation: target engagement without clinical benefit

The chelation hypothesis was epidemiologically plausible. TACT2 notes that worldwide analyses estimated more than 5.5 million cardiovascular deaths in 2019 attributable to low-to-moderate lead exposure, that cadmium is ubiquitous and atherogenic, and that an American Heart Association scientific statement recognized lead, cadmium, and arsenic as risk factors for atherosclerosis [2]. The earlier TACT trial reported an 18% reduction in cardiovascular events with EDTA chelation in patients with prior myocardial infarction, and a 41% reduction in the diabetes subgroup; in 2014, the American College of Cardiology and American Heart Association assigned EDTA chelation a class IIb recommendation [2].

TACT2 directly tested this strategy in a more targeted population. It was a multicenter, double-masked, placebo-controlled 2 × 2 factorial trial in participants aged 50 years or older with diabetes and prior myocardial infarction, randomizing 1,000 participants to 40 weekly EDTA-based or placebo infusions and also randomizing high-dose oral multivitamins and minerals versus placebo, though the cited report addresses the chelation comparison [2]. In the primary analysis population of 959 participants who received at least one infusion, the primary composite of all-cause mortality, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina occurred in 35.6% of the chelation group and 35.7% of the placebo group, with an adjusted hazard ratio of 0.93 (95% CI 0.76–1.16; P = .53) [2]. Five-year cumulative incidence was 45.8% with chelation and 46.5% with placebo [2]. Secondary cardiovascular death, myocardial infarction, or stroke showed no significant difference (hazard ratio 0.89, 95% CI 0.66–1.19), and all-cause mortality was similar (hazard ratio 0.96, 95% CI 0.71–1.30) [2].

The trial nevertheless demonstrated biological target engagement: median blood lead fell from 9.03 μg/L at baseline to 3.46 μg/L at the 40th infusion, a 61% reduction, whereas placebo changed little [2]. Urine cadmium levels did not show a clinically relevant sustained preinfusion reduction, although cadmium excretion transiently increased after infusion [2]. Serious adverse events were similar between groups, and no unexpected serious adverse events occurred [2]. The authors concluded that, despite effectively reducing blood lead, EDTA chelation was not effective in reducing cardiovascular events in stable patients with coronary artery disease, diabetes, and prior myocardial infarction, and that the findings do not support clinical use of chelation for cardiovascular risk reduction in U.S. and Canadian participants with diabetes and prior myocardial infarction [2].

The discrepancy with TACT is unresolved but partly explained by changing population exposure and statistical uncertainty. TACT2 participants had more advanced disease and higher event rates, which would usually favor a larger treatment effect, yet the result was null [2]. The authors note that population blood lead levels declined between the two trials, with NHANES median blood lead falling 35% from 17 to 11 μg/L and lead in air pollution decreasing 88% since 2010, potentially reducing the therapeutic target available for chelation [2]. Bayesian sensitivity analyses using skeptical or pessimistic priors were inconsistent with clinically consequential benefit, whereas optimistic priors based on TACT suggested a possible smaller effect, with a posterior hazard ratio of 0.81 (95% credible interval 0.68–0.96) under the TACT diabetes-subgroup prior [2]. The trial was designed assuming a 30% relative reduction and would have been underpowered to detect the 18% reduction seen in TACT [2]. Thus, the evidence refutes routine use of EDTA chelation for secondary prevention in the tested population, while leaving open the possibility that earlier trials overestimated a smaller effect or that populations with higher residual lead exposure might behave differently.

## Sodium–potassium substitution: hard-outcome evidence with population limits

Among interventions in the supplied evidence, the Salt Substitute and Stroke Study provides hard-outcome evidence for modifying sodium and potassium intake. SSaSS was an open-label, cluster-randomized trial involving 20,995 people from 600 villages in rural China who had a history of stroke or were 60 years of age or older with uncontrolled hypertension; patients with severe kidney disease and those taking potassium supplements or potassium-sparing diuretics were excluded [9]. The intervention group used a salt substitute of approximately 75% sodium chloride and 25% potassium chloride, while the control group continued regular salt [9].

In the Medscape report of the trial results, mean follow-up was 4.74 years and systolic blood pressure was reduced by 3.3 mmHg in the substitute group [9]. The outcome and safety statistics are summarized below [9].

| Outcome | Salt-substitute rate | Regular-salt rate | Effect estimate |
| --- | --- | --- | --- |
| Stroke [9] | 29.14 events per 1000 person-years [9] | 33.65 events per 1000 person-years [9] | rate ratio 0.86 (95% CI 0.77–0.96; P = .006) [9] |
| Major cardiovascular events [9] | 49.09 events per 1000 person-years [9] | 56.29 events per 1000 person-years [9] | rate ratio 0.87 (95% CI 0.80–0.94; P < .001) [9] |
| Death [9] | 39.28 events per 1000 person-years [9] | 44.61 events per 1000 person-years [9] | rate ratio 0.88 (95% CI 0.82–0.95; P < .001) [9] |
| Serious adverse events attributed to hyperkalemia [9] | 3.35 events per 1000 person-years [9] | 3.30 events per 1000 person-years [9] | rate ratio 1.04 (95% CI 0.80–1.37; P = .76) [9] |

In the Medscape report, Neal said the way the body manages sodium and potassium and their association with blood pressure is highly consistent across populations, and he stated that almost everyone, except people with serious kidney disease, should expect some benefit from switching to a salt substitute [9]. The same report conveyed Neal’s interpretation that 7% to 8% of the control group began using the substitute during the study, which may have underestimated the true effect, and that the product was low-cost and easy to manufacture, costing around 50% more than regular salt or roughly a dollar or two per person per year [9]. These are investigators’ interpretations as reported in a secondary news article, not independent trial measurements [9].

The same Medscape report noted that an accompanying editorial gave a less enthusiastic response: Julie R. Ingelfinger pointed out that serial monitoring of potassium levels was not performed, so hyperkalemic episodes may not have been detected, and persons with conditions associated with hyperkalemia were not studied [9]. The editorial also noted that household members without risk factors were not analyzed and that wider effectiveness is hard to predict given limited generalizability [9]. Taken together, the reported trial results indicate that sodium–potassium substitution can reduce hard cardiovascular outcomes in a high-risk rural Chinese population, but the evidence does not establish that the same substitution is safe or equally effective in all populations, especially those at risk for hyperkalemia [9].

## Magnesium and selenium: feasible supplementation with surrogate or fragile effects

Magnesium supplementation is feasible and has a small blood-pressure effect. An umbrella meta-analysis of 10 meta-analyses including 8,610 participants found that magnesium supplementation significantly reduced systolic blood pressure by 1.25 mmHg (95% CI −1.98 to −0.51) and diastolic blood pressure by 1.40 mmHg (95% CI −2.04 to −0.75), although heterogeneity was high (I² = 92% for systolic and 93% for diastolic pressure) [3]. In subgroup analysis, doses of at least 400 mg/day were associated with larger reductions: systolic pressure by 6.38 mmHg (95% CI −11.56 to −1.19) and diastolic pressure by 3.71 mmHg (95% CI −6.88 to −0.53) [3]. Studies lasting at least 12 weeks showed smaller but significant effects: systolic pressure by 0.42 mmHg (95% CI −0.78 to −0.06) and diastolic pressure by 0.45 mmHg (95% CI −0.76 to −0.14) [3]. The authors note that the effect is not large enough to recommend magnesium as antihypertensive monotherapy, but it may be clinically meaningful as a dietary supplement alongside other antihypertensive treatments [3].

The magnesium evidence is mechanistically plausible but outcome-limited. Proposed mechanisms include nitric oxide release, vasodilation, reduced vascular tone, anti-inflammatory and antioxidant effects, and interaction with calcium and potassium pathways [3]. Previous meta-analyses have conflicted: one reported benefit on systolic but not diastolic pressure, and another found no beneficial effect on either, underscoring heterogeneity and population dependence [3]. The supplied magnesium evidence addresses blood pressure, not cardiovascular events, so it supports risk-factor modification rather than proven prevention or treatment of cardiovascular disease outcomes.

A more targeted magnesium intervention in kidney disease is also feasible but surrogate. In a single-center randomized controlled trial in hemodialysis patients, increasing dialysate magnesium from 1.0 to 2.0 mEq/L for 28 days raised serum magnesium by 0.88 mg/dL (95% CI 0.66–1.10) and increased T50, a measure of serum calcification propensity, by 73 minutes (95% CI 30–116; P < 0.001) compared with standard dialysate magnesium [6]. Lower T50 represents higher calcification propensity and is associated with greater cardiovascular risk and death in end-stage kidney disease, but the trial did not measure cardiovascular events [6]. This establishes biological feasibility and a favorable biomarker signal, not clinical efficacy.

Selenium supplementation has shown metabolic marker changes in heart failure, but the evidence is small and fragile. In a randomized double-blind placebo-controlled trial of 53 patients with congestive heart failure, 200 µg/day selenium as selenium yeast for 12 weeks reduced serum insulin and HOMA-IR, increased QUICKI, lowered LDL cholesterol and total-to-HDL cholesterol ratio, increased HDL cholesterol, and reduced high-sensitivity C-reactive protein while increasing total antioxidant capacity and glutathione compared with placebo [5]. However, after Bonferroni correction for multiple testing, QUICKI, LDL cholesterol, high-sensitivity C-reactive protein, total antioxidant capacity, and glutathione became non-significant [5]. The trial reported no side effects, but it did not verify plasma or urine selenium levels, and baseline selenium status was unknown, limiting interpretation of whether the intervention corrected deficiency or produced excess [5]. The authors also cite prior evidence that selenium supplementation did not significantly affect all-cause mortality, cardiovascular mortality, non-fatal cardiovascular events, or all cardiovascular events, and that another randomized trial reported increased type 2 diabetes incidence with selenium supplementation [5]. Selenium therefore remains a supplementation strategy with surrogate effects and unresolved safety and efficacy boundaries.

## Copper and zinc: observational risk markers, not proven therapeutic targets

Copper has emerged as an observational risk marker. In NHANES 2011–2016, 5,412 adults representing 76,479,702 individuals were followed for a mean of 5.85 years, with 96 cardiovascular deaths and 356 all-cause deaths [8]. Compared with the lowest serum copper tertile, the highest tertile was associated with cardiovascular mortality (hazard ratio 7.06, 95% CI 1.85–26.96) and all-cause mortality (hazard ratio 2.84, 95% CI 1.66–4.87), with a linear dose-response relationship [8]. A meta-analysis of three additional prospective cohorts including 13,189 patients confirmed an association between higher serum copper and cardiovascular disease (hazard ratio 2.08, 95% CI 1.63–2.65) and all-cause mortality (hazard ratio 1.89, 95% CI 1.58–2.25) [8]. The authors explicitly state that causal relationships require further investigation [8].

Copper-to-zinc balance has also been linked to incident heart failure. In a prospective cohort of 1,866 Finnish men aged 42–61 years followed for a median of 26.5 years, 365 heart failure cases occurred [10]. A unit increase in serum copper-to-zinc ratio was associated with heart failure risk after adjustment for nutritional and other confounders (hazard ratio 1.63, 95% CI 1.06–2.51) [10]. Serum copper alone was associated with heart failure risk (hazard ratio 2.42, 95% CI 1.32–4.44), whereas serum zinc alone was not statistically significant (hazard ratio 1.34, 95% CI 0.50–3.63) [10]. Addition of the copper-to-zinc ratio improved heart failure risk prediction [10]. These findings provide a rationale for studying copper or zinc modulation, but they do not show that lowering copper, raising zinc, or altering the ratio improves cardiovascular outcomes. The supplied evidence contains no randomized cardiovascular endpoint trials of zinc supplementation, and the copper evidence is observational; this is a limit of the available evidence, not proof that such trials are absent.

## Hepcidin, ferroptosis, and other iron-axis strategies: early-stage and non-cardiovascular

The hepcidin-ferroportin axis regulates systemic iron homeostasis: hepcidin binds ferroportin and induces its internalization and proteasomal degradation, blocking iron release from cells into the circulation [7]. Iron chelation with deferasirox reduces labile plasma iron within hours and produces sustained decreases in iron burden over extended treatment periods; in the ESCALATOR study, deferasirox produced clinically meaningful reductions in liver iron concentration and serum ferritin in heavily iron-overloaded beta-thalassemia patients [7]. Erythropoietic modulators have hematologic efficacy: luspatercept reduced transfusion burden in transfusion-dependent beta-thalassemia (21.4% versus 4.5% with placebo in BELIEVE) and increased transfusion independence in myelodysplastic syndromes (38% versus 13% in MEDALIST; 60.4% versus 34.8% versus erythropoiesis-stimulating agents in COMMANDS) [7].

These applications are hematologic rather than cardiovascular: the supplied review frames hepcidin modulators as treatments for iron overload and iron-restrictive anemias, including anemia of chronic disease and certain cancer-related anemias, and ferroptosis-targeting agents such as erastin and RSL3 as oncology strategies [7]. Safety concerns limit translation: chronic hepcidin suppression may increase susceptibility to infection because hepcidin helps sequester iron from circulating pathogens; hepcidin agonists for iron overload must be dosed carefully to avoid iron-restricted erythropoiesis and anemia; and systemic induction of ferroptosis risks off-target toxicity in non-malignant tissues, including the heart, liver, and kidney [7]. Clinical development of hepcidin modulators has also faced challenges from the complexity of iron regulation and potential off-target effects [7]. Within the supplied review, the cited efficacy data concern transfusion-dependent thalassemia, myelodysplastic syndromes, iron overload, and anemia of inflammation, not cardiovascular endpoints, so hematologic feasibility cannot be equated with proven cardiovascular efficacy [7].

## Overall assessment and unresolved questions

The evidence supports therapeutic metal-ion modulation in two main cardiovascular contexts: correcting iron deficiency in heart failure and altering sodium–potassium intake in selected high-risk populations. Intravenous iron reduces heart-failure hospitalization and a composite cardiovascular endpoint, but the mortality signal remains uncertain and the benefit is tied to deficiency status, dosing intensity, and formulation-specific safety considerations [1] [4]. Salt substitution reduces stroke, major cardiovascular events, and death, but the trial’s population, exclusion of kidney disease and potassium-related risk, and lack of serial potassium monitoring limit broad generalization [9]. Magnesium supplementation is feasible and modestly lowers blood pressure, but the supplied evidence does not establish cardiovascular outcome benefit [3]. Dialysate magnesium can raise serum magnesium and improve a calcification-propensity biomarker in hemodialysis, but it remains surrogate [6]. Selenium supplementation can improve metabolic markers in small trials, but results are fragile and cardiovascular outcome evidence is lacking [5]. Copper and zinc are associated with cardiovascular risk in prospective cohorts, but no interventional outcome evidence is supplied [8] [10]. EDTA chelation is the clearest counterexample: it lowered blood lead effectively but did not reduce major adverse cardiovascular events in TACT2 [2].

The most consequential uncertainty is whether observational associations translate into benefit when the ion is therapeutically modulated. TACT2 shows that target engagement does not guarantee clinical efficacy: lead lowering occurred without event reduction, possibly because population lead exposure had declined or because the prior effect size was overestimated [2]. Conversely, IV iron shows that a therapy can reduce hospitalization without definitively reducing mortality, and its benefit may depend on identifying true deficiency and maintaining adequate dosing [1] [4]. Salt substitution shows that hard outcomes can improve through a simple dietary intervention, but safety and generalizability remain constrained by kidney disease and hyperkalemia risk [9].

A judgment that metal-ion modulation is broadly effective for cardiovascular prevention is not supported. A narrower judgment is supported: deficiency-specific iron repletion in heart failure and sodium–potassium substitution in selected high-risk populations have clinical evidence, while supplementation or chelation aimed at other ions remains unproven for cardiovascular outcomes. The supplied evidence extends to a 2025 intravenous iron meta-analysis [1] and a 2024 TACT2 trial [2], but it does not provide 2026 guideline updates or completed trials of zinc modulation, copper lowering, hepcidin modulation, or dialysate magnesium with cardiovascular endpoints. Evidence that would change the assessment includes randomized trials of copper or zinc modulation with hard cardiovascular outcomes, cardiovascular outcome trials of hepcidin or ferroptosis-targeted agents, longer magnesium outcome trials, and safety data on potassium substitution in populations excluded from SSaSS.

## References

[1] Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency | Nature Medicine — https://www.nature.com/articles/s41591-025-03671-1
[2] Edetate Disodium–Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical Trial - PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC11325247/
[3] Impact of Magnesium Supplementation on Blood Pressure: An Umbrella Meta-Analysis of Randomized Controlled Trials - PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC11401110/
[4] Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis - PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC10116902/
[5] Selenium supplementation lowers insulin resistance and markers of cardio-metabolic risk in patients with congestive heart failure: a randomised, double-blind, placebo-controlled trial | British Journal of Nutrition | Cambridge Core — https://doi.org/10.1017/s0007114518001253
[6] The Effect of Increasing Dialysate Magnesium on Serum Calcif... : Clinical Journal of the American Society of Nephrology — https://journals.lww.com/cjasn/fulltext/2018/09000/the_effect_of_increasing_dialysate_magnesium_on.12.aspx
[7] Therapeutic targeting of the hepcidin-ferroportin axis and erythropoietic modulators: a narrative review - PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC12722858
[8] Association of serum copper (Cu) with cardiovascular mortality and all-cause mortality in a general population: a prospective cohort study - PubMed — https://pubmed.ncbi.nlm.nih.gov/37915007
[9] Salt Substitute Reduces Stroke, CV Events, and Death — https://www.medscape.com/viewarticle/957472
[10] Serum copper-to-zinc ratio is associated with heart failure and improves risk prediction in middle-aged and older Caucasian men: A prospective study - PubMed — https://pubmed.ncbi.nlm.nih.gov/35680488


Please begin the extraction now. Output only the JSON list directly, without any chitchat or explanations.